Novo Nordisk (NYSE:NVO) gave investors a lot of what they wanted on Wednesday. Third-quarter sales rose 4% at constant exchange rates to about $11.9 billion, ahead of Wall Street estimates closer to $11 billion. Sales of obesity drugs jumped 22%. And the company raised its full-year outlook again, now calling for sales growth of anywhere from a 2% decline to a 2% gain. In August, it was expecting a decline of up to 6%. The stock rose about 5% to more than $42 on Wednesday, but the question investors keep asking, according to one analyst, is about next year, and that's the one Novo wouldn't answer. Image source: Novo Nordisk.
CryptoAlerta — análise de criptomoedas e mercado em tempo real